Parkinson's disease (PD) affects over 4 million people worldwide.
The principal photoreceptors for image-forming vision in the retina PD symptoms result from relentless destruction of nigral dopaminergic are rod and cone cells. Loss of photoreceptor cells, as happens in a neurons, and current treatments do not cure or even slow disease pronumber of human diseases, such as retinitis pigmentosa and age-related gression. In humans with advanced PD, the subthalamic nucleus macular degeneration, leads to irreversible blindness. Unfortunately, (STN) is hyperactive. In primates administered a toxin causing dopathe current therapeutic treatment for retinal degeneration is very limminergic cell death, STN hyperactivity results, and bilateral STN deep ited. Here, we asked whether it is possible to restore any vision by brain stimulation (DBS) modifies this activity. We are leading a pilot ectopic expression of melanopsin, a newly discovered light-sensitive trial of subthalamic DBS in 30 subjects with early stage PD to gather photopigment, in the surviving ganglion cells. The protein melanopin preliminary safety and tolerability information necessary to launch a is normally expressed in 2-3% of the ganglion cell population of the large-scale multicenter trial. With approval from the Vanderbilt Unimouse retina. To test this intriguing possibility, we used a viral vector versity IRB and an Investigational Device Exemption from the FDA, to express mammalian melanopsin in other retinal ganglion cells of 30 subjects with early stage PD were enrolled from our clinic and rd/rd mice, which suffer an early degeneration of rod photoreceptors through advertising. Inclusion criteria were subjects aged 50-75 years and a subsequent degeneration of cones. In each retina, melanopsin old with Hoehn and Yahr Stage II idiopathic PD who had been on PD was expressed in up to 6,000 retinal ganglion cells, of many morphomedications greater than 6 months but less than 4 years, and were logical types. Whole-cell patch-clamp recording showed intrinsic phowithout motor fluctuations or dyskinesias. Exclusions included dementoresponses in these cells, even after degeneration of the photoreceptia, major psychiatric disease, or previous brain operation or injury. tors and additional pharmacological or Cd ++ block of synaptic function. We report here the first evaluation of STN activity in eight subjects
The newly melanopsin-expressing ganglion cells provided an enhancewith early PD and compare these results to 8 age-and gender-matched ment of visual function in the rd/rd mice: the pupillary light reflex controls with advanced PD. The early PD group included seven males returned almost to normal; the mice showed behavioral avoidance of and one female, aged 57.4 ± 1.1 years. The advanced PD group were light in an open field test; and they could discriminate a light stimulus eight age-and gender-matched patients with Hoehn and Yahr Stage ≥ from a dark one in a two-choice visual discrimination alley. These III PD who were treated with DBS as standard of care. The Unified results show that an effective signaling pathway for melanopsin is not Parkinson's Disease Rating Scale (UPDRS-III) was 27.0 ± 3.1 off restricted to the retinal ganglion cells that normally contain melanopmedication for the early PD patients, and 42.3 ± 4.0 for the advanced sin, or to any particular ganglion cell type. Expression of this or other patients. Intraoperative microelectrode recording of firing rates and light-sensitive proteins in the surviving retinal neurons might provide background activity was utilized during implantation to identify STN some degree of vision for humans blind due to photoreceptor degenerand surrounding nuclei. A subsequent analysis of the microelectrode ation. recordings of the STN from both advanced and early PD patients for
